OSCR
Oscar Health, Inc.
OSCR has the edge over STIM overall, supported by lower modeled downside and stronger fundamentals.
STIM
Neuronetics, Inc.
STIM offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
STIM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
STIM's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
STIM PE Valuation
STIM has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
STIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect STIM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over STIM on earnings quality, reporting a profit while its opponent remains loss making.
STIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.33 | +$0.50 |
| Q2 2026 | -$0.44 | +$0.70 |
| Q1 2026 | -$0.54 | +$0.78 |
| Q4 2025 | -$0.59 | +$0.79 |
| Q3 2025 | -$0.83 | +$0.38 |
| Q2 2025 | -$1.14 | -$0.04 |
| Q1 2025 | -$1.32 | -$0.38 |
| Q4 2024 | -$1.38 | -$0.33 |
STIM is still losing money, but far less than before: $0.33 per share over the past year, against $1.87 at its worst in mid-2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over STIM on profitability, with a higher operating margin.
STIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42M | +13% |
| Q2 2026 | $41.6M | +9.1% |
| Q1 2026 | $34.5M | +7.8% |
| Q4 2025 | $41.8M | +86% |
| Q3 2025 | $37.3M | +101% |
| Q2 2025 | $38.1M | +132% |
| Q1 2025 | $32M | +84% |
| Q4 2024 | $22.5M | +11% |
STIM has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.3% | +21 points |
| Q2 2026 | -3.6% | +18 points |
| Q1 2026 | -26% | +8.3 points |
| Q4 2025 | -12% | +39 points |
| Q3 2025 | -20% | +22 points |
| Q2 2025 | -21% | +31 points |
| Q1 2025 | -34% | +4.9 points |
| Q4 2024 | -51% | -29 points |
STIM's operating margin was 1.3% last quarter, up 21 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over STIM on cash generation, producing positive trailing cash flow while its opponent burns cash.
STIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $768K | +$1.7M |
| Q2 2026 | -$1.4M | +$2.3M |
| Q1 2026 | -$9.6M | +$7.6M |
| Q4 2025 | $692K | +$9.4M |
| Q3 2025 | -$899K | +$4.9M |
| Q2 2025 | -$3.8M | +$1.8M |
| Q1 2025 | -$17.2M | -$4.8M |
| Q4 2024 | -$8.7M | -793% |
STIM has burned cash in almost every quarter: −$10M over the past year, against −$31M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
STIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.3% | +3.9M shares |
| 1 year | +14% | +9.7M shares |
| 3 years | +169% | +48.4M shares |
| 5 years | +197% | +51.1M shares |
| Available history | +313% | +58.4M shares |
STIM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
STIM Net Leverage
STIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
STIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 17.8 | Oversold |
STIM's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STIM PE vs Healthcare Sector
STIM has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over STIM on trend strength, trading above more of its moving averages.
STIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.11 | 32% below |
| 20 week MA | $2.29 | 38% below |
| 50 week MA | $1.82 | 21% below |
| 100 week MA | $2.57 | 44% below |
| 200 week MA | $2.47 | 42% below |
STIM is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over STIM on returns for 2026, with the stronger performance.
STIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.50 | $10.7 | +137% |
| 2021 | $10.7 | $4.60 | -57% |
| 2022 | $4.60 | $5.97 | +30% |
| 2023 | $5.97 | $2.90 | -51% |
| 2024 | $2.90 | $1.48 | -49% |
| 2025 | $1.48 | $1.42 | -4.1% |
| 2026 YTD | $1.42 | $1.43 | +0.7% |
STIM has finished three years in a row lower, and it's up 0.7% so far in 2026.